Shots:
Antengene has licensed ATG-106, a preclinical CDH6×CD3 bispecific T-cell engager for solid tumors, to K2 Therapeutics & granted an option for exclusive rights to a second undisclosed bispecific TCE candidate, covering all global markets excl. Greater China
As per the licensing deal, Antengene will receive $20M in upfront & near-term consideration, incl. cash &…
